Is Tilray Inc (TLRY) overvalued? · rev $821.3M
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Tilray Inc (TLRY) looks expensive on cached numbers — not a short thesis.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
TLRY currently screens at market cap $573.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TLRY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TLRY stock page for the full model, not this heading.
Not investment advice.